

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

expert testimony, employment, or other affiliations patent

Non-Financial Support: Examples include drugs/equipment



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Fernando	2. Surname (Last Name) Martinez	3. Date 05-September-2019
4. Are you the corresponding author?	Yes V No	Corresponding Author's Name Wisia Wedzicha
5. Manuscript Title Can macrolide antibiotics prevent hosp	ital readmissions?	
6. Manuscript Identifying Number (if you kn Blue-201905-0957ED	ow it)	
Section 2. The Work Under Co	onsideration for Public	ation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	ubmitted work.
of compensation) with entities as descri	bed in the instructions. Us port relationships that wer est?	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication .
Name of Entity	Gianic	n-Financial Other? Comments
AstraZeneca		COPD Advisory Boards (personal fees and non-personal travel support); Study Steering Committee (personal

Martinez 2

fees and non-personal travel support), ALAT presentation (personal fees and non-financial

travel support)

7



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Boehringer Ingelheim		✓	V	V	COPD Advisory Board (personal fees and non-personal travel support); ATS presentation (personal fees); IPF disease state presentation at ALAT (personal fee and non-personal travel support); Progressive pulmonary fibrosis DSMB (no financial support but travel); ERS IPF study result presentation (personal fee and travel support)
ProterrixBio			✓	√	COPD Scientific Advisory Board (no direct financial compensation, support for NIH study)
Columbia University		V			COPD CME program (personal fee honoraria)
Genentech		✓	V		COPD Advisory Board (personal fee and non-personal travel support) and asthma DSMB (no support); IPF Advisory Board (personal fees honorarium and non-personal travel support)
GlaxoSmithKline		✓	V		COPD Advisory Boards (personal fees honoaria and non-personal travel support), Study Steering Committee (non-personal travel support), DSMB (other - academic co-authorship), ERS presentation (non-personal travel support)
Inova Fairfax Health System		✓	✓		COPD CME presentation (personal support honoarium and non-personal travel support)
MD Magazine		✓			COPD CME program (personal fee honorarium and non-personal travel support)
Methodist Hospital Brooklyn		✓			IPF CME program (personal fee honoraria)
Miller Communicatinos		✓	/		COPD and IPF CME programs (personal fees honoraria and non- personal travel support)
National Association for Continuing Education		✓	/		COPD and IPF CME programs (perfonal fees honoraria and non- personal travel support)
Novartis		✓	/		COPD Advisory Board and International meeting COPD disease presentations (personal fees honoraria and non personal travel support).



New York University	✓			ILD CME program (personal fee honoraria)
Pearl Pharmaceuticals	√	/		COPD Advisory Boards (personal fee honoraria and non-personal travel support) AND COPD Steering Committee (academic productivity)
PeerView Communications	\checkmark	✓		COPD and IPF CME programs (personal fees honoraria and non- personal travel support)
Prime Communications	✓	✓		COPD CME programs (personal fees honoraria and non-personal travel support)
Puerto Rican Respiratory Society	✓	✓		COPD and IPF CME program (personal fee honoraria and non- personal travel support)
Chiesi	✓	✓		COPD CME presentation (personal fees honoraria and non-personal travel support); Advisory Board (personal fees honoraria and travel support)
Sunovion	\checkmark	✓		COPD Advisory Boards (personal fee honoraria and non-personal travel support)
Theravance	✓	V		COPD Advisory Board (personal fee honoraria and non-personal travel support)
UpToDate	✓			COPD CME (personal fee honoraria)
WebMD/MedScape	✓			COPD CME presentations (personal fee honoraria)
Afferent/Merck			✓	IPF Study Steering Committee (other - co-authorship)
Gilead		√		IPF Study Steering Committee (other - co-authorship)
Nitto		V		IPF Study Teleconference and Steering Committee (non-personal travel support)
Patara/Respivant	✓		✓	Venture capital expert advice for IPF Study (personal fees honoraria); IPF Steering Committee
Potomac	✓	✓		IPF CME presentations (personal fee honoraria and non-personal travel support)
Biogen			✓	IPF Study DSMB (no support) and IPF Study Steering Committee (academic productivity)
University of Alabama Birmingham	✓	✓		IPF CME presentation (personal fee honoraria and non-personal travel support)



Veracyte				✓	IPF Study Steering Committee (other co-authorship)
Zambon			✓		IPF Study Meeting (non-personal travel support) and Advisory Board (personal fees honorarium)
American Thoracic Society		✓			AJRCCM DE (personal fee honoraria)
NIH	✓				IPF UO1, COPD UO1, RO1
Physicians Education Resource		\checkmark	✓		COPD CME program (personal fee honorarium and travel support)
Rockpointe		\checkmark			COPD CME program (personal fee honorarium)
Prometic				✓	IPF Steering Committee (academic productivity)
Rare Disease Healthcare Communications		✓			IPF CME program (personal fee honorarium)
Bayer				✓	IPF Steering Committee (academic productivity)
Bridge Biotherapeutics				✓	IPF Advisor (academic productivity)
Canadian Respiratory Network		\checkmark	✓		COPD CME presentation (honorarium and travel support)
ProMedior				✓	IPF Steering Committee (academic productivity)
-eva		✓	/		COPD Advisory Board (personal fee honorarium and travel support)
rance Foundation		✓			IPF CME program
Dartmouth		✓	✓		IPF CME program
Gala				✓	COPD Advisory Board
Physicians Education Resource		✓			COPD CME



Costion F	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	
Section 0.	Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Martinez reports grants from Department of Defense, during the conduct of the study; personal fees, non-financial support and other from AstraZeneca, personal fees, non-financial support and other from Boehringer Ingelheim, nonfinancial support and other from ProterrixBio, personal fees from Columbia University, personal fees and non-financial support from Genentech, personal fees and non-financial support from GlaxoSmithKline, personal fees and non-financial support from Inova Fairfax Health System, personal fees from MD Magazine, personal fees from Methodist Hospital Brooklyn, personal fees and non-financial support from Miller Communicatinos, personal fees and non-financial support from National Association for Continuing Education, personal fees and non-financial support from Novartis, personal fees from New York University, personal fees and non-financial support from Pearl Pharmaceuticals, personal fees and nonfinancial support from PeerView Communications, personal fees and non-financial support from Prime Communications, personal fees and non-financial support from Puerto Rican Respiratory Society, personal fees and non-financial support from Chiesi, personal fees and non-financial support from Sunovion, personal fees and non-financial support from Theravance, personal fees from UpToDate, personal fees from WebMD/MedScape, other from Afferent/Merck, non-financial support from Gilead, non-financial support from Nitto, personal fees and other from Patara/Respivant, personal fees and non-financial support from Potomac, other from Biogen, personal fees and non-financial support from University of Alabama Birmingham, other from Veracyte, non-financial support from Zambon, personal fees from American Thoracic Society, grants from NIH, personal fees and non-financial support from Physicians Education Resource, personal fees from Rockpointe, other from Prometic, personal fees from Rare Disease Healthcare Communications, other from Bayer, other from Bridge Biotherapeutics, personal fees and non-financial support from Canadian Respiratory Network, other from ProMedior, personal fees and non-financial support from Teva, personal fees from France Foundation, personal fees and non-financial support from Dartmouth, other from Gala, personal fees from Physicians Education Resource, outside the submitted work; .



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

Relevant financial activities outside the submitted work. 3.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Ritchie 1



Section 1. Ide	entifying Informatio	on		
1. Given Name (First Na Andrew		Surname (Last Name) cchie		3. Date 16-June-2019
4. Are you the correspo	onding author?	Yes 🗸 No	Corresponding Author's Nam Prof Wedzicha	ne
5. Manuscript Title CAN MACROLIDE AN	TIBIOTICS PREVENT HO	SPITAL READMISSION	NS?	
6. Manuscript Identifyii Blue-201905-0957ED	ng Number (if you know i	t)		
			_	
Section 2. The	e Work Under Consi	deration for Publi	cation	
any aspect of the subm statistical analysis, etc.)	itted work (including but		n a third party (government, com ata monitoring board, study desi	nmercial, private foundation, etc.) for ign, manuscript preparation,
Section 3. Re	levant financial acti	vities outside the	submitted work.	
of compensation) wit clicking the "Add +" k	th entities as described	in the instructions. U	•	tionships (regardless of amount dd as many lines as you need by onths prior to publication.
Section 4. Int	ellectual Property	- Patents & Copyri	ghts	
Do you have any pate	ents, whether planned,	pending or issued, b	roadly relevant to the work?	☐ Yes ✓ No

Ritchie 2



Section 5.	
	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
none	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Ritchie 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Information	ation				
1. Given Name (First Name) Jadwiga	2. Surnar Wedzich	me (Last Nar a	me)		3. Date 28-May-2019
4. Are you the corresponding author?	✓ Yes	No			
5. Manuscript Title Can macrolide antibiotics prevent hospi	tal readm	issions?			
6. Manuscript Identifying Number (if you kno	ow it)				
Section 2. The Work Under Co	nsiderat	tion for P	ublication		
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interest	but not lim		nts, data monitoring		
Section 3. Relevant financial a	ctivities	outside '	the submitted v	work.	
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report there any relevant conflicts of interest lf yes, please fill out the appropriate information.	oed in the ort relationst?	instruction onships tha Yes	ns. Use one line fo	r each er	ntity; add as many lines as you need by
Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments
SSK	√				Research grant to Institution 100.000 USD
ohnson and Johnson	✓				Research grant to Institution 200,000USD
Novartis				✓	Meeting expenses only / no personal fees since January 2015
Boehringer Ingelheim				✓	Meeting expenses only / no personal fees since January 2015
Astra Zeneca				✓	Meeting expenses only / no personal fees since January 2015



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
GSK				✓	Meeting expenses only / no personal fees since January 2015		
GSK	Research grant for Early COPD cohort 1,000,000 USD						
Astra Zeneca	✓				Research grant for Early COPD cohort1,000,000USD		
Boehringer Ingelheim	✓				Research grant for Early COPD cohort1,000.000 USD		
Novartis	✓				Research grant for Early COPD cohort 1,000.000 USD		
Chiesi	\checkmark				Research grant for Early COPD cohort 1,000.000 USD		
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No							
Section 5. Relationships not o	overed	above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the following relationships/conc	litions/cir	cumstance	s are present (exp	olain belo	ow):		
No other relationships/conditions/ci	cumstan	ces that pre	esent a potential	conflict o	finterest		
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Wedzicha reports grants from GSK, grants from Johnson and Johnson, other from Novartis, other from Boehringer Ingelheim, other from Astra Zeneca, other from GSK, grants from GSK, grants from Astra Zeneca, grants from Boehringer Ingelheim, grants from Novartis, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.